Alumni

Alumni
3T Biosciences is solving major bottleneck in the field of immunotherapy - identifying
Alumni
QuickFire
Challenge Winner
At Ab Initio, we are using a proprietary directed evolution engineering technology to
Alumni
Achelois’ mission is to develop effective and nontoxic therapeutics to inhibit tumors, and
Alumni
Adicet is developing a novell cell therapy platform.
Alumni
Targeting sensitized nerves to treat chronic & debilitating neurogenic disorders
Alumni
Agenovir is developing a novel class of nuclease-based anti-viral therapeutics for
Alumni
Annexon is developing novel therapeutics for neurodegenerative and autoimmune disorders.
Alumni
New Pathways for Next Generation Biological, Peptide and RNA Therapeutics.
Alumni
Audentes is a biotechnology company committed to the development and commercialization of
Alumni
Targeted medicines for neurodevelopmental disorders
Alumni
Our mission is to create antifibrotic treatment strategies that address a wide variety of
Alumni
Encoded Genomics analyses the human genome for information which may be of use in drug
Alumni
QuickFire
Challenge Winner
EpiBiome, Inc. is a precision microbiome engineering company based in San Francisco,
Alumni
Fibralign Corporation is a developer of advanced biomedical devices that utilizes
Alumni
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of